Targets for LDL-lowering therapy.

Area of Science:

• Cardiovascular Medicine
• Lipidology
• Clinical Trials

Background:

• Residual cardiovascular risk persists despite LDL-lowering therapies.
• Non-HDL-cholesterol (non-HDL-C) and apolipoprotein B (apoB) are key lipid markers.
• Current assessment often focuses on in-trial reductions, not residual risk identification.

Purpose of the Study:

• To compare non-HDL-C and apoB as therapeutic targets for LDL-lowering.
• To evaluate which marker better identifies residual cardiovascular risk post-treatment.
• To inform optimal lipid management strategies.

Main Methods:

• Review of data from recent clinical trials (e.g., JUPITER, MERCURY II, TNT, CTT).
• Analysis of studies comparing non-HDL-C and apoB in identifying residual risk.
• Comparative assessment of marker performance in diverse patient populations.

Main Results:

• Apolipoprotein B (apoB) demonstrates superior ability in identifying residual cardiovascular risk compared to non-HDL-C.
• In-trial data comparison is insufficient for assessing residual risk identification.
• Evidence from multiple statin trials supports apoB's enhanced predictive value.

Conclusions:

• While in-trial marker reduction is important, assessing residual risk identification is critical.
• Apolipoprotein B (apoB) significantly outperforms non-HDL-C in identifying patients at residual risk.
• Targeting apoB may offer a more accurate approach to managing cardiovascular risk.